• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Reardon Robert

    4/18/25 4:30:40 PM ET
    $RAIN
    Industrial Machinery/Components
    Technology
    Get the next $RAIN alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Reardon Robert

    (Last) (First) (Middle)
    4851 TAMIAMI TRAIL N,
    SUITE 200

    (Street)
    NAPLES FL 34103

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    04/01/2025
    3. Issuer Name and Ticker or Trading Symbol
    Rain Enhancement Technologies Holdco, Inc. [ RAIN ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ ROBERT REARDON 04/18/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $RAIN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RAIN

    DatePrice TargetRatingAnalyst
    5/30/2023Buy → Neutral
    ROTH MKM
    3/21/2023$11.00Outperform
    SVB Securities
    1/31/2023$21.00Buy
    ROTH Capital
    1/23/2023$18.00Buy
    Mizuho
    9/12/2022$10.00Buy
    H.C. Wainwright
    4/1/2022$15.00Outperform
    Oppenheimer
    9/14/2021$22.00Neutral
    Goldman
    7/20/2021$25.00Overweight
    Piper Sandler
    More analyst ratings

    $RAIN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Rain Oncology Inc. (Amendment)

      SC 13G/A - Rain Oncology Inc. (0001724979) (Subject)

      2/14/24 5:14:27 PM ET
      $RAIN
      Industrial Machinery/Components
      Technology
    • SEC Form SC 13G/A filed by Rain Oncology Inc. (Amendment)

      SC 13G/A - Rain Oncology Inc. (0001724979) (Subject)

      2/14/24 4:19:28 PM ET
      $RAIN
      Industrial Machinery/Components
      Technology
    • SEC Form SC 13G/A filed by Rain Oncology Inc. (Amendment)

      SC 13G/A - Rain Oncology Inc. (0001724979) (Subject)

      2/7/24 7:45:02 AM ET
      $RAIN
      Industrial Machinery/Components
      Technology

    $RAIN
    SEC Filings

    See more
    • SEC Form EFFECT filed by Rain Enhancement Technologies Holdco Inc.

      EFFECT - Rain Enhancement Technologies Holdco, Inc. (0002028293) (Filer)

      4/28/25 12:15:05 AM ET
      $RAIN
      Industrial Machinery/Components
      Technology
    • SEC Form 424B3 filed by Rain Enhancement Technologies Holdco Inc.

      424B3 - Rain Enhancement Technologies Holdco, Inc. (0002028293) (Filer)

      4/25/25 4:20:34 PM ET
      $RAIN
      Industrial Machinery/Components
      Technology
    • SEC Form POS AM filed by Rain Enhancement Technologies Holdco Inc.

      POS AM - Rain Enhancement Technologies Holdco, Inc. (0002028293) (Filer)

      4/17/25 9:51:47 PM ET
      $RAIN
      Industrial Machinery/Components
      Technology

    $RAIN
    Leadership Updates

    Live Leadership Updates

    See more
    • Rain Enhancement Technologies Holdco, Inc. Announces Management Updates and Appointment of Randy Seidl as Chief Executive Officer

      Technology Industry Veteran With Over 30 Years Of Enterprise Leadership Experience To Accelerate RET's Growth And Commercialization Strategy Rain Enhancement Technologies Holdco, Inc. ("RET Holdco" or the "Company") (NASDAQ:RAIN, RAINW)), an emerging company developing rainfall generation technology, today announced that Randy Seidl has been appointed as Chief Executive Officer ("CEO") of RET Holdco and of its wholly-owned subsidiary, Rain Enhancement Technologies, Inc. ("RET"). Seidl has served as Co-Chief Executive Officer and a member of the Board of Directors since January 2, 2025. Seidl brings over three decades of experience scaling technology companies and driving revenue growth.

      2/3/25 8:00:00 AM ET
      $ONDS
      $RAIN
      Radio And Television Broadcasting And Communications Equipment
      Technology
      Industrial Machinery/Components

    $RAIN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Dacier Paul T bought $150,040 worth of shares (13,173 units at $11.39) (SEC Form 4)

      4 - Rain Enhancement Technologies Holdco, Inc. (0002028293) (Issuer)

      2/10/25 4:54:42 PM ET
      $RAIN
      Industrial Machinery/Components
      Technology
    • Large owner Dacier Paul T bought $100,027 worth of shares (8,782 units at $11.39) (SEC Form 4)

      4 - Rain Enhancement Technologies Holdco, Inc. (0002028293) (Issuer)

      12/31/24 7:50:27 PM ET
      $RAIN
      Industrial Machinery/Components
      Technology
    • Tang Kevin C bought $279,030 worth of shares (284,145 units at $0.98) (SEC Form 4)

      4 - Rain Oncology Inc. (0001724979) (Issuer)

      10/13/23 4:57:52 PM ET
      $RAIN
      Industrial Machinery/Components
      Technology

    $RAIN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Reardon Robert

      3 - Rain Enhancement Technologies Holdco, Inc. (0002028293) (Issuer)

      4/18/25 4:30:40 PM ET
      $RAIN
      Industrial Machinery/Components
      Technology
    • SEC Form 3 filed by new insider Peperzak Marcus

      3 - Rain Enhancement Technologies Holdco, Inc. (0002028293) (Issuer)

      4/11/25 4:01:05 PM ET
      $RAIN
      Industrial Machinery/Components
      Technology
    • Large owner Dacier Paul T bought $150,040 worth of shares (13,173 units at $11.39) (SEC Form 4)

      4 - Rain Enhancement Technologies Holdco, Inc. (0002028293) (Issuer)

      2/10/25 4:54:42 PM ET
      $RAIN
      Industrial Machinery/Components
      Technology

    $RAIN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rain Enhancement Technologies Holdco, Inc. Announces Management Updates and Appointment of Randy Seidl as Chief Executive Officer

      Technology Industry Veteran With Over 30 Years Of Enterprise Leadership Experience To Accelerate RET's Growth And Commercialization Strategy Rain Enhancement Technologies Holdco, Inc. ("RET Holdco" or the "Company") (NASDAQ:RAIN, RAINW)), an emerging company developing rainfall generation technology, today announced that Randy Seidl has been appointed as Chief Executive Officer ("CEO") of RET Holdco and of its wholly-owned subsidiary, Rain Enhancement Technologies, Inc. ("RET"). Seidl has served as Co-Chief Executive Officer and a member of the Board of Directors since January 2, 2025. Seidl brings over three decades of experience scaling technology companies and driving revenue growth.

      2/3/25 8:00:00 AM ET
      $ONDS
      $RAIN
      Radio And Television Broadcasting And Communications Equipment
      Technology
      Industrial Machinery/Components
    • Pathos AI Completes Acquisition of Rain Oncology

      Rain Stockholders to Receive $1.16 Per Share in Cash Plus Contingent Value Rights Pathos AI, Inc. ("Pathos") today announced that it has, through its wholly owned subsidiary WK Merger Sub, Inc. ("Merger Sub"), successfully completed its tender offer to acquire all outstanding shares of the common stock of Rain Oncology Inc. (NASDAQ:RAIN) ("Rain") for $1.16 per share in cash plus one contingent value right per share (each, a "CVR"), which CVR shall represent the right to receive potential payments pursuant to the terms and subject to the conditions of the Contingent Value Rights Agreement, dated as of January 26, 2024, by and among Pathos, Merger Sub, Equiniti Trust Company, LLC, and Forti

      1/26/24 8:49:00 AM ET
      $RAIN
      Industrial Machinery/Components
      Technology
    • Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights

      NEWARK, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NASDAQ:RAIN) ("Rain"), today announced it has entered into a definitive merger agreement whereby Pathos AI, Inc. ("Pathos") will acquire Rain for $1.16 in cash per share plus a non-tradeable contingent value right (a "CVR") for potential cash payments of up to approximately $0.17 per share. The Rain Board of Directors voted unanimously to approve the proposed Offer, Merger and related transactions contemplated by the Merger Agreement (collectively, the "Transaction"). The upfront cash consideration represents a 17% premium over Rain's unaffected stock price as of October 13, 2023. The Rain Board reached this determinati

      12/13/23 6:05:30 PM ET
      $RAIN
      Industrial Machinery/Components
      Technology

    $RAIN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rain Oncology downgraded by ROTH MKM

      ROTH MKM downgraded Rain Oncology from Buy to Neutral

      5/30/23 10:27:43 AM ET
      $RAIN
      Industrial Machinery/Components
      Technology
    • SVB Securities initiated coverage on Rain Oncology with a new price target

      SVB Securities initiated coverage of Rain Oncology with a rating of Outperform and set a new price target of $11.00

      3/21/23 8:58:11 AM ET
      $RAIN
      Industrial Machinery/Components
      Technology
    • ROTH Capital resumed coverage on Rain Oncology with a new price target

      ROTH Capital resumed coverage of Rain Oncology with a rating of Buy and set a new price target of $21.00

      1/31/23 9:10:39 AM ET
      $RAIN
      Industrial Machinery/Components
      Technology

    $RAIN
    Financials

    Live finance-specific insights

    See more
    • Rain Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update

      – Evaluating a number of opportunities to diversify pipeline in precision oncology – – Submitted data abstracts for milademetan in both MANTRA and MANTRA-2 clinical studies; anticipated presentations at medical conferences in 4Q23 – – Quarter-end cash position of $86.3 million expected to provide runway into year-end 2026 – – Management to host conference call and webcast today at 2:00 pm PT/5:00 pm ET – NEWARK, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NASDAQ:RAIN), (Rain), today reports financial results for the second quarter ended June 30, 2023, and provides a corporate update. "Rain has been aggressively pursuing a multitude of opportunities as we seek to leve

      8/10/23 4:05:00 PM ET
      $RAIN
      Industrial Machinery/Components
      Technology
    • Rain Oncology to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on August 10, 2023

      NEWARK, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NASDAQ:RAIN), ("Rain") today announced it will report financial results for the second quarter ended June 30, 2023 and provide a corporate update on Thursday, August 10, 2023. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company's business and financial results. Conference Call and Webcast Details: Date: August 10, 2023Time: 2:00 pm PT (5:00 pm ET)Dial In Numbers: 1 (888) 886-7786 (U.S. Toll Free) / 1 (416) 764-8658 (International)Conference ID: 29873479Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1624922&tp_key=7933f8175f A replay of the ca

      7/26/23 8:00:00 AM ET
      $RAIN
      Industrial Machinery/Components
      Technology
    • Rain Oncology Announces Topline Results from Phase 3 MANTRA Trial of Milademetan for the Treatment of Dedifferentiated Liposarcoma

      – The Phase 3 MANTRA trial did not meet the primary endpoint of progression free survival vs. standard of care – – The median PFS was 3.6 months for milademetan versus 2.2 months for trabectedin with a hazard ratio of 0.89 – – Rain to host a conference call at 8:30 a.m. ET – NEWARK, Calif., May 22, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NASDAQ:RAIN), (Rain), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced its topline pivotal Phase 3 MANTRA data. The trial, evaluating the efficacy, safety, and tolerability of milademetan in p

      5/22/23 8:00:00 AM ET
      $RAIN
      Industrial Machinery/Components
      Technology